This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Real validated EIF1 Western blot protocols, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-EIF1 WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~12.7 kDa | |
| Gel | 12–15% | |
| Negative control | siRNA / KO lysate |
| PTM | Phosphorylated + Acetylated | |
| Caveat | Phosphorylation-induced band shift | |
| Regulation | TNFα up | |
| Isoform | 1 isoform(s) |
Literature-validated Western blot parameters for EIF1 — gel percentage, transfer, blocking, antibody incubation and detection, extracted from published methods.
| Sample / lysate | human Hela , Lane 2: human HEK293 , Lane 3: human Jurkat , Lane 4: human Raji , Lane 5: human K562 , Lane 7: rat pancreas , Lane 8: mouse pancreas , Lane 9: mouse NIH/3T3 . After electrophoresis, proteins were transferred to a nitrocellulose membrane at 150 mA for 50-90 minutes. Blocked the membrane with 5% non-fat milk/TBS for 1.5 hour at RT. The membrane was incubated with rabbit anti-EIF1 antigen affinity purified polyclonal antibody (Catalog # A04125-1) at 0.5 μg/mL overnight at 4°C, then washed with TBS-0.1%Tween 3 times with 5 minutes each and probed with a goat anti-rabbit IgG-HRP secondary antibody at a dilution of 1:5000 for 1.5 hour at RT. The signal is developed using an Enhanced Chemiluminescent detection (ECL) kit (Catalog # EK1002) with Tanon 5200 system. A specific band was detected for EIF1 at approximately 13 kDa. The expected band size for EIF1 is at 13 kDa |
| Gel % | 12–15% |
| Load | 30 ug |
| Transfer | nitrocellulose membrane, 150 mA, 50–90 min |
| Membrane | nitrocellulose |
| Blocking | 5% non-fat milk / TBS, 1.5 h RT |
| Primary antibody | 0.5 µg/mL |
| Primary incubation | overnight at 4 °C |
| Secondary antibody | goat anti-rabbit IgG-HRP, 1:5000 |
| Wash | TBS-0.1% Tween, 3 × 5 min |
| Detection | ECL |
| Exposure / imaging | Tanon 5200 |
| Observed band | 13 kDa |
EIF1 is a ~12.7 kDa cytoplasmic protein with no glycosylation, disulfide dimerization, or cleavage, running as a single band near predicted mass, occasionally shifted by phosphorylation.
| Single sharp band near 12-13 kDa | matches the unmodified full-length EIF1 monomer, consistent with no glycosylation or dimerization |
| No higher-molecular-weight smear above the main band | EIF1 has no annotated N- or O-glycosylation sites, so glycoform smearing is not expected |
| No band near ~25 kDa under non-reducing conditions | EIF1 has no annotated disulfide bonds, so it does not form a covalent homodimer |
| No smaller cleaved fragment relative to the main band | EIF1 has no signal peptide or propeptide, so the translated product is already the mature protein |
| Band present in whole-cell or cytoplasmic lysate | EIF1 is cytoplasmic, not secreted, so it is retained intracellularly and detectable in standard lysates |
| Faint doublet or slight upward shift near the main band | N-terminal acetylation and phosphorylation at Ser2/Ser9 can produce a minor mobility shift or a closely spaced secondary band |
| Predicted mass (12.7 kDa, 113 aa) | sets the baseline expected migration position with no other modifiers applied |
| Absence of glycosylation (0 annotated sites) | keeps the band sharp and close to predicted mass rather than smeared upward |
| Absence of disulfide bonds (0 annotated) | prevents covalent homodimer formation, so no ~25 kDa band appears even without full reduction |
| No signal peptide or propeptide | means the full-length translated product is the mature cytoplasmic form, with no smaller cleaved species |
| N-terminal acetylation and phosphorylation (Ser2, Ser9) | can cause a small upward mobility shift or a minor doublet rather than a true mass change |
| Single isoform (no alternative splicing) | means only one band is expected rather than multiple isoform-driven bands |
| Situation | Likely cause | Next action |
|---|---|---|
| Weak or no signal | EIF1 is small and low-abundance and can transfer through membrane pores or be lost during processing | use a shorter transfer time or lower voltage, a 0.2 um pore membrane, and confirm loading with a low-MW-range stain |
| Band higher than expected | N-terminal acetylation and phosphorylation at Ser2/Ser9 add mass and can retard migration slightly above 12.7 kDa | treat this modest shift as expected for native EIF1 rather than evidence of a wrong band |
| Multiple bands | EIF1 functions alongside related 43S pre-initiation complex partners, and antibodies can cross-react with similar translation factors | confirm specificity with a knockdown or knockout lysate control and compare the pattern to the antibody datasheet |
| Fragments below expected size | as a small cytoplasmic protein, EIF1 is susceptible to proteolytic degradation during lysis and handling | lyse in cold buffer with fresh protease inhibitors and minimize sample handling time before loading |
| Band lower than expected | at only 113 aa and 12.7 kDa, EIF1 migrates near the dye front on standard gels and can run off or be underestimated | use a higher-percentage gel (15-18%) or a Tricine-SDS-PAGE system suited for resolving low-molecular-weight proteins |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|
| Tissue | Cell type | Level | Evidence | Source |
|---|
Deeper troubleshooting and optimisation questions for EIF1, answered from its protein features.
BosterBio's EIF1 antibodies are among the best-performing WB antibodies on the market — well cited, thoroughly validated, and orthogonally cross-validated against negative tissues and complementary methods.
The recommended anti-EIF1 antibody below is a best-performing, extensively cited reagent, thoroughly validated for Western blot and orthogonally cross-validated against negative-tissue controls and complementary detection methods, ensuring confident, specific detection of EIF1 in your samples.
Which to pick: Only one Boster anti-EIF1 antibody is catalogued, A04125-1, so it is the clear choice; it includes an actual Western blot validation image demonstrating specific EIF1 detection, giving confidence in its performance for your assay.